Article
A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 May 2015
Blumenschein G R, Smit E F, Planchard D, Kim D-W, Cadranel J, De Pas T, Dunphy F, Udud K, Ahn M-J, Hanna N H, Kim J-H, Mazieres J, Kim S-W, Baas P, Rappold E, Redhu S, Puski A, Wu F S, Jänne P A
Abstract excerpt
BACKGROUND: KRAS mutations are detected in 25% of non-small-cell lung cancer (NSCLC) and no targeted therapies are approved for this subset population. Trametinib, a selective allosteric inhibitor of MEK1/MEK2, demonstrated preclinical and clinical activity in KRAS-mutant NSCLC. We report a phase II trial comparing trametinib with docetaxel in patients with advanced KRAS-mutant NSCLC. PATIENTS AND METHODS:...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.